Pregled bibliografske jedinice broj: 1077950
Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth? // International journal of environmental research and public health, 17 (2020), 18; 6566, 7 doi:https://.org/10.3390/ijerph17186566 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1077950 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pregnancy in Patients with Type One Diabetes
Mellitus Treated with Continuous Subcutaneous
Insulin Infusion—Preconception Basal Insulin
Dose as a Potential Risk Factor for Fetal
Overgrowth?
Autori
Lekšić, Gloria ; Baretić, Maja ; Ivanišević, Marina ; Jurišić-Eržen, Dubravka
Izvornik
International journal of environmental research and public health (1660-4601) 17
(2020), 18;
6566, 7
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
type one diabetes mellitus ; pregnancy ; preconception ; insulin pump ; large-for-gestational-age neonates
Sažetak
Despite widespread use of technology, type one diabetes mellitus (T1DM) is still a great clinical challenge during pregnancy. This study aims to assess how prenatal variables of T1DM patients using continuous subcutaneous insulin infusion (CSII) influence pregnancy outcomes. We performed a retrospective study of 35 patients with T1DM treated with CSII during pregnancy. Alterable preconception variables (A1C, body mass index, basal and bolus insulin dose) were analysed as possible contributors to birth weight and large-for-gestational-age (LGA) prevalence. Inclusion criteria were presence of T1DM for more than two years, A1C < 7.4% and treatment with CSII for at least three months prior to conception. The preconception basal insulin dose and A1C had a significant correlation to the neonatal birth weight (p = 0.01, r = 0.4 and p = 0.04, r = 0.3, respectively) and were significant in regression analysis together contributing 22% of the variance in birth weight percentiles (sig = 0.17, R square = 0.22). Prevalence of LGA was 46%. Women who had LGA neonates also had a higher preconception basal insulin dose compared to women with non-LGA neonates (26 ± 9 vs. 18 ± 7 IU (international units), p = 0.01). The LGA group had a higher preconception A1C, but it did not reach statistical significance (6.5 ± 0.5% vs. 6.2 ± 0.9%, respectively, p = 0.2). Women with T1DM treated with CSII who had unregulated glycaemia and more basal insulin were at greater risk for development of LGA neonates
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Klinički bolnički centar Rijeka
Profili:
Maja Baretić
(autor)
Gloria Lekšić
(autor)
Dubravka Jurišić-Eržen
(autor)
Marina Ivanišević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE